SA News • Feb. 24, 2014
There is research on this stock available only to PRO subscribers.
From other sites
Feb. 24, 2014, 8:00 AM
- Bayer (BAYZF) is on course to acquire partner Algeta (ALGZF) after the German company received acceptance representing 92.17% of the Norwegian company's stock for its $2.9B bid.
- Bayer has also extended the acceptance deadline of the offer by two days to Wednesday and it expects to close the deal in Q1.
- The acquisition will give Bayer full control of Xofigo, a prostate-cancer treatment that the German drugs and chemicals firm has developed with Algeta since 2009.
- Bayer views Xofigo, which was launched in the U.S. last year, as one of its five most important new medicines. (PR)
Dec. 19, 2013, 7:25 AM
- Bayer (BAYZF) has increased its offer for partner Algeta (ALGZF) to $2.9B from an initial bid of $2.41B, with the proposal receiving support from the Norwegian company's board.
- The acquisition would give Bayer full control of Xofigo, a prostate-cancer treatment that the German drugs and chemicals firm has developed with Algeta since 2009.
- Bayer views Xofigo, which was launched in the U.S. this year, as one of its five most important new medicines. (PR)
Nov. 26, 2013, 2:13 AM
- Bayer (BAYZF) has offered 14.76B Norwegian kroner ($2.41B) to acquire partner Algeta (ALGZF), with the bid of 336 kroner a share representing a 27% premium to the latter's last closing price.
- Earlier this month, Bayer and Algeta received EU marketing approval for prostate-cancer treatment Xofigo. (PR)
Jan. 28, 2013, 10:40 AMImmunomedics (IMMU +3.3%) says its entered into an agreement with Algeta ASA (ALGZF.PK) for the development of a potential cancer treatment using IMMU's humanized anti-CD22 antibody, epratuzumab. Under the terms of the agreement, IMMU will provide clinical-grade antibody to Algeta, which has rights to evaluate epratuzumab for the treatment of cancer. Algeta will fund all preclinical and clinical development costs up to the end of Phase I testing. | 1 Comment
There are no StockTalks on this stock yet.
ALGZF vs. ETF Alternatives
Other News & PR